GlassScriptPhysician profile
Nimit Sudan
NPI 1437199924
$2,655.68
in general payments reported to CMS, 2019-2025
8 companies · $30.65 in 2025
The $30.65 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.66 · 2020: $23.29 · 2022: $1,162 · 2023: $787 · 2024: $641 · 2025: $30.65.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,050 · Honoraria: $200 · Food and Beverage: $145 · Education: $63.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,050.00 |
| Honoraria | $200.00 |
| Food and Beverage | $145.33 |
| Education | $63.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $1,179.48 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $1,050.00 | 2023-2024 | Calquence, Truqap |
| Daiichi Sankyo INC. | $200.00 | 2023 | |
| Intuitive Surgical, INC. | $95.85 | 2024 | |
| Pfizer INC. | $54.31 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $32.75 | 2023 | Iclusig |
| Seagen INC. | $23.29 | 2020 | |
| Erbe USA INC | $20.00 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nimit Sudan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.